Literature DB >> 31402149

Human TIGIT on porcine aortic endothelial cells suppresses xenogeneic macrophage-mediated cytotoxicity.

Yuki Noguchi1, Akira Maeda2, Pei-Chi Lo1, Chihiro Takakura1, Tomoko Haneda1, Tasuku Kodama1, Tomohisa Yoneyama1, Chiyoshi Toyama1, Yuko Tazuke1, Hiroomi Okuyama1, Shuji Miyagawa3.   

Abstract

PURPOSE: The delayed rejection caused by strong cell-mediated innate and adaptive xenogeneic immune responses continues to be a major obstacle. Therefore, suppressing macrophage function could be effective in avoiding this type of rejection. In this study, the suppression of T-cell immunoglobulin and ITIM domain (TIGIT) function against macrophage-mediated xenogeneic rejection was investigated.
MATERIAL AND METHODS: Naïve porcine aortic endothelial cell (PAEC) and PAEC transfectant with TIGIT (PAEC/TIGIT) were co-cultured with M1 macrophages, and the degree of cytotoxicity was determined by a counting beads assay. The anti/pro-inflammatory gene expression was determined by RT-PCR and the phosphorylated SHP-1 in the macrophages after co-culturing with PAEC or PAEC/TIGIT was evaluated by western blotting.
RESULTS: CD155 was expressed at essentially equal levels on both M1 and M2 macrophages, whereas TIGIT was highly expressed on M2 macrophages but not in M1 macrophages. TIGIT on PAEC significantly reduced the cytotoxicity of M1 macrophages but no significant suppression of phagocytosis was detected. TIGIT also caused a decrease in the expression of pro-inflammatory cytokines, namely TNFα, IL-1β and IL-12 in M1 macrophages. Furthermore, PAEC/TIGIT caused a significant increase in phosphorylated SHP-1 in M1 macrophages compared to PAEC.
CONCLUSION: The findings of this study indicate that TIGIT suppresses xenogeneic M1 macrophage-induced cytotoxicity, probably at least in part, via the phosphorylation of SHP-1. In addition, the reduced expression of some pro-inflammatory cytokines, namely TNFα, IL-1β and IL-12, was observed in M1 macrophages that had been cultured with PAEC/TIGIT.
Copyright © 2019 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Macrophage; Pig-to-Human; TIGIT; Xenotransplantation

Mesh:

Substances:

Year:  2019        PMID: 31402149     DOI: 10.1016/j.imbio.2019.07.008

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  6 in total

1.  Suppression of xenogeneic innate immune response by a membrane-type human surfactant protein-A.

Authors:  Chiyoshi Toyama; Akira Maeda; Shuhei Kogata; Riho Yamamoto; Kazunori Masahata; Takehisa Ueno; Masafumi Kamiyama; Yuko Tazuke; Hiroshi Eguchi; Hiroomi Okuyama; Shuji Miyagawa
Journal:  Exp Ther Med       Date:  2022-07-26       Impact factor: 2.751

Review 2.  Update in TIGIT Immune-Checkpoint Role in Cancer.

Authors:  Tiziana Annese; Roberto Tamma; Domenico Ribatti
Journal:  Front Oncol       Date:  2022-05-17       Impact factor: 5.738

3.  Noncoding RNA 886 alleviates tumor cellular immunological rejection in host C57BL/C mice.

Authors:  Hui Ma; Miao Wang; Ying Zhou; Jia-Jie Yang; Li-Yong Wang; Rong-Hui Yang; Min-Jie Wen; Lu Kong
Journal:  Cancer Med       Date:  2020-05-31       Impact factor: 4.452

Review 4.  Aspects of the Complement System in New Era of Xenotransplantation.

Authors:  Shuji Miyagawa; Akira Maeda; Chiyoshi Toyama; Shuhei Kogata; Chizu Okamatsu; Riho Yamamoto; Kazunori Masahata; Masafumi Kamiyama; Hiroshi Eguchi; Masahito Watanabe; Hiroshi Nagashima; Masahito Ikawa; Katsuyoshi Matsunami; Hiroomi Okuyama
Journal:  Front Immunol       Date:  2022-04-14       Impact factor: 8.786

5.  Prognostic value of TIGIT in East Asian patients with solid cancers: A systematic review, meta-analysis and pancancer analysis.

Authors:  Sicong Li; Lanxing Li; Tianyan Pan; Xiaoqun Li; Yujia Tong; Yongdong Jin
Journal:  Front Immunol       Date:  2022-09-21       Impact factor: 8.786

Review 6.  Recent Advances of Immune Checkpoint Inhibition and Potential for (Combined) TIGIT Blockade as a New Strategy for Malignant Pleural Mesothelioma.

Authors:  Sophie Rovers; Annelies Janssens; Jo Raskin; Patrick Pauwels; Jan P van Meerbeeck; Evelien Smits; Elly Marcq
Journal:  Biomedicines       Date:  2022-03-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.